双吲哚类生物碱的抗肿瘤活性研究进展  

Research progress of bis-indolic alkaloids diversities as potential anticancer agents

作　　者：王丽平[1] 邓桂英 徐沙丽[1] Wang Li-ping;Deng Gui-ying;Xu Sha-li(Liyuan Hospital Affiliated to Tongji Medical College,Huazhong University of Science and Technology,Wuhan 100191)

机构地区：[1]华中科技大学同济医学院附属梨园医院神经内科,武汉100191

出　　处：《中国抗生素杂志》2021年第2期97-103,共7页Chinese Journal of Antibiotics

基　　金：华中科技大学自主创新基金(No.2012QN051)。

摘　　要：癌症是仅次于心脑血管疾病的第二大类致死性疾病,每年数百万人因此丧生。抗肿瘤药物对癌症的防治至关重要,然而目前的抗肿瘤药物特异性普遍较差,往往会导致各种副作用。不仅如此,日益严峻的耐药性问题使得现有药物的疗效呈逐年下降之势。因此,亟需开发新型抗肿瘤药物。双吲哚类生物碱具有结构特殊、类药性强、选择性高和毒副作用小等特点,在抗肿瘤方面的活性引起了药物研发人员的普遍关注。本文从结构特点和生物活性方面,总结了近年来双吲哚类生物碱的抗肿瘤领域的最新研究进展。Cancer is the second largest cause of death after cardiovascular disease,leading to millions of deaths annually.Anticancer agents are crucial for the treatment of cancers,but the low specificity of the current accessible drugs usually results in various side effects.Moreover,the increasing emergency of drug-resistant cancers makes the anticancer agents less and less effective.Thus,it is imperative to develop novel anticancer agents.The anticancer activity of bis-indolic alkaloids diversities is well known,due to their novel structure,excellent bioactivity,high selectivity,and low side effects.This review focused on the recent research progress of bis-indolic alkaloids diversities as potential anticancer agents.

关 键 词：双吲哚类生物碱 抗癌 构-效关系 

分 类 号：R9[医药卫生—药学]